Status:
COMPLETED
Liver-enriched Antimicrobial Peptide 2
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborating Sponsors:
Gubra ApS
Conditions:
Type 2 Diabetes
Eligibility:
MALE
18-25 years
Phase:
EARLY_PHASE1
Brief Summary
The investigators aim to investigate the physiological importance of LEAP-2 in healthy volunteers focusing on its potential insulinotropic effects.
Detailed Description
The dramatic and almost immediate effects of Roux-en-Y gastric bypass (RYGB) surgery on type 2 diabetes (T2D) can only in part be explained by alterations in the plasma concentrations of known peptide...
Eligibility Criteria
Inclusion
- Caucasian men
- Age between 18 and 25 years
- Body mass index between 20-25 kg/m2
- Informed consent
Exclusion
- Anaemia (haemoglobin below normal range)
- ALAT and/or ASAT \>2 times normal values or history of hepatobiliary and/or gastrointestinal disorder(s)
- Nephropathy (serum creatinine above normal range and/or albuminuria)
- Any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses
- Any ongoing medication that the investigator evaluates would interfere with trial participation.
- First- and second-degree relatives with diabetes
- Regular tobacco smoking
Key Trial Info
Start Date :
January 28 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04043065
Start Date
January 28 2019
End Date
May 20 2019
Last Update
May 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Clinical Metabolic Research
Hellerup, Denmark, 2900